Madrigal Pharmaceuticals, Inc.
MDGL· Nasdaq
Released Feb 27, 2019, before the open
10-K filed Feb 27, 2019, 58 days after period end · 0001047469-19-000725
| Metric | Q4 2018 | Q4 2017 | Q4 2016dderived from reported figures | Q4 2015 |
|---|---|---|---|---|
| Revenue | $0.00 | — | — | — |
| Net Income | -$11.48M | -$8.45M | -$7.75M | — |
Madrigal Pharmaceuticals, Inc. · CIK 1157601 · Engraved from SEC EDGAR
| EPS Diluted | -$0.75 | -$0.67 | — | -$0.08 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.